Neogen (NASDAQ:NEOG - Get Free Report) released its earnings results on Friday. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.12, Briefing.com reports. The company had revenue of $231.30 million during the quarter, compared to the consensus estimate of $227.16 million. Neogen had a negative net margin of 2.58% and a positive return on equity of 2.80%. The company's revenue was up .7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.11 EPS. Neogen updated its FY 2025 guidance to EPS.
Neogen Stock Performance
Shares of NASDAQ:NEOG traded down $0.71 during trading on Friday, reaching $12.36. 7,059,031 shares of the company's stock traded hands, compared to its average volume of 3,064,322. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.41 and a quick ratio of 2.79. The company has a 50 day moving average of $13.54 and a 200-day moving average of $15.11. Neogen has a 12 month low of $11.46 and a 12 month high of $18.75. The stock has a market capitalization of $2.68 billion, a P/E ratio of -112.36 and a beta of 1.23.
Wall Street Analyst Weigh In
Several analysts have issued reports on NEOG shares. StockNews.com upgraded Neogen to a "sell" rating in a research note on Monday, September 30th. Guggenheim initiated coverage on Neogen in a research report on Thursday, December 19th. They set a "buy" rating and a $15.00 price target on the stock.
Get Our Latest Research Report on NEOG
Neogen Company Profile
(
Get Free Report)
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.
Featured Articles
Before you consider Neogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neogen wasn't on the list.
While Neogen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
